In contrast, Gefitinib attenuates the sensitivity to NK cells, suggesting that therapy targeting EGFR-TKI may be a “double-edged sword” as they inhibit cell proliferation while abetting immune escape from host immunity in NSCLC cells. This evidence concerns the gene EGFR and non-small cell lung carcinoma.